Bank Of America Corp Nektar Therapeutics Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Nektar Therapeutics stock. As of the latest transaction made, Bank Of America Corp holds 42,246 shares of NKTR stock, worth $52,385. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,246

Previous 160,357 73.66%

Holding current value

$52,385

Previous $89,000 56.18%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.49 - $0.96 $57,874 - $113,386	-118,111 Reduced 73.66%	42,246 $39,000
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.57 $7,981 - $10,831	-19,003 Reduced 10.59%	160,357 $89,000
Q2 2023 Aug 14, 2023	SELL	$0.53 - $1.03 $41,456 - $80,565	-78,219 Reduced 30.37%	179,360 $104,000
Q1 2023 May 12, 2023	BUY	$0.64 - $3.15 $38,597 - $189,973	60,309 Added 30.57%	257,579 $180,000
Q4 2022 Feb 10, 2023	SELL	$2.03 - $4.28 $360,318 - $759,687	-177,497 Reduced 47.36%	197,270 $445,000

Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $153,726 - $259,919	50,568 Added 15.6%	374,767 $1.2 Million
Q2 2022 Aug 12, 2022	BUY	$3.17 - $6.17 $824,028 - $1.6 Million	259,946 Added 404.57%	324,199 $1.23 Million
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $242,403 - $799,464	-58,270 Reduced 47.56%	64,253 $346,000
Q4 2021 Feb 08, 2022	SELL	$10.83 - $18.41 $560,463 - $952,735	-51,751 Reduced 29.7%	122,523 $1.66 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $567,159 - $817,542	43,394 Added 33.16%	174,274 $3.13 Million
Q2 2021 Sep 13, 2021	BUY	$16.52 - $20.4 $2.16 Million - $2.67 Million	130,880 New	130,880 $2.25 Million

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Nektar Therapeutics Transaction History